PharVision Advisers LLC Takes $453,000 Position in Cencora, Inc. (NYSE:COR)

PharVision Advisers LLC acquired a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 2,016 shares of the company's stock, valued at approximately $453,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of COR. Hickory Asset Management Inc. acquired a new position in shares of Cencora during the fourth quarter worth $572,000. Sylvest Advisors LLC purchased a new position in Cencora during the 4th quarter worth $1,105,000. Vontobel Holding Ltd. increased its position in Cencora by 46.9% during the 4th quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock valued at $1,403,000 after buying an additional 1,995 shares in the last quarter. Milestone Asset Management LLC raised its stake in Cencora by 430.2% in the fourth quarter. Milestone Asset Management LLC now owns 5,461 shares of the company's stock valued at $1,227,000 after buying an additional 4,431 shares during the last quarter. Finally, Portfolio Design Labs LLC boosted its holdings in Cencora by 76.9% in the fourth quarter. Portfolio Design Labs LLC now owns 11,032 shares of the company's stock worth $2,479,000 after acquiring an additional 4,794 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Robert W. Baird upped their price objective on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Wall Street Zen upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Bank of America lifted their price objective on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Citigroup upped their target price on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Finally, Wells Fargo & Company raised their target price on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $301.18.

Cencora Stock Performance

NYSE:COR traded up $2.12 during mid-day trading on Monday, hitting $292.23. The company's stock had a trading volume of 1,356,427 shares, compared to its average volume of 1,546,285. The business's fifty day moving average is $282.42 and its two-hundred day moving average is $257.20. The stock has a market cap of $56.64 billion, a price-to-earnings ratio of 41.57, a PEG ratio of 1.31 and a beta of 0.60. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $309.35.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. The firm had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The company's revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.80 earnings per share. Analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 2nd. Stockholders of record on Friday, May 16th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.75%. The ex-dividend date is Friday, May 16th. Cencora's dividend payout ratio (DPR) is 25.52%.

Insider Activity at Cencora

In other news, EVP Elizabeth S. Campbell sold 4,127 shares of the business's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $268.28, for a total value of $1,107,191.56. Following the completion of the sale, the executive vice president now directly owns 14,665 shares in the company, valued at $3,934,326.20. The trade was a 21.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Robert P. Mauch sold 4,969 shares of the company's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the transaction, the chief executive officer now directly owns 47,582 shares of the company's stock, valued at approximately $13,766,900.06. The trade was a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 45,223 shares of company stock worth $12,369,767 in the last three months. Company insiders own 10.80% of the company's stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.